Xiomara A Perez
Overview
Explore the profile of Xiomara A Perez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
810
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bordia T, Perez X
Eur J Neurosci
. 2018 Jun;
49(6):859-868.
PMID: 29923650
L-dopa induced dyskinesias (LIDs) are a disabling motor complication of L-dopa therapy for Parkinson's disease (PD) management. Treatment options remain limited and the underlying network mechanisms remain unclear due to...
2.
Perez X, Zhang D, Bordia T, Quik M
Mov Disord
. 2017 Mar;
32(4):538-548.
PMID: 28256010
Background: Dyskinesias are a disabling motor complication that arises with prolonged l-dopa treatment. Studies using D1 receptor drugs and genetically modified mice suggest that medium spiny neurons expressing D1 receptors...
3.
Bordia T, Zhang D, Perez X, Quik M
Exp Neurol
. 2016 Sep;
286:32-39.
PMID: 27658674
Tardive dyskinesia (TD) is a drug-induced movement disorder that arises with antipsychotics. These drugs are the mainstay of treatment for schizophrenia and bipolar disorder, and are also prescribed for major...
4.
Bordia T, Perez X, Heiss J, Zhang D, Quik M
Neurobiol Dis
. 2016 Feb;
91:47-58.
PMID: 26921469
L-dopa-induced dyskinesias (LIDs) are a serious complication of L-dopa therapy for Parkinson's disease. Emerging evidence indicates that the nicotinic cholinergic system plays a role in LIDs, although the pathways and...
5.
Zhang D, McGregor M, Bordia T, Perez X, McIntosh J, Decker M, et al.
Mov Disord
. 2015 Nov;
30(14):1901-1911.
PMID: 26573698
Background: ABT-126 is a novel, safe, and well-tolerated α7 nicotinic receptor agonist in a Phase 2 Alzheimer's disease study. We tested the antidyskinetic effect of ABT-126 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys...
6.
Perez X
Neuropsychol Rev
. 2015 Nov;
25(4):371-83.
PMID: 26553323
One of the primary deficits in Parkinson's disease (PD) is the loss of dopaminergic neurons in the substantia nigra pars compacta which leads to striatal dopaminergic deficits that underlie the...
7.
Quik M, Bordia T, Zhang D, Perez X
Int Rev Neurobiol
. 2015 Oct;
124:247-71.
PMID: 26472532
Parkinson's disease is a progressive neurodegenerative disorder associated with tremor, rigidity, and bradykinesia, as well as nonmotor symptoms including autonomic impairments, olfactory dysfunction, sleep disturbances, depression, and dementia. Although the...
8.
Perez X, Khroyan T, McIntosh J, Quik M
Pharmacol Res Perspect
. 2015 Feb;
3(1):e00105.
PMID: 25692023
An important factor contributing to the high relapse rates among smokers is nicotine withdrawal symptoms. Multiple studies suggest that decreased dopamine release in nucleus accumbens plays a key role in...
9.
Quik M, Zhang D, Perez X, Bordia T
Pharmacol Ther
. 2014 May;
144(1):50-9.
PMID: 24836728
A large body of evidence using experimental animal models shows that the nicotinic cholinergic system is involved in the control of movement under physiological conditions. This work raised the question...
10.
Perez X, McIntosh J, Quik M
J Neurochem
. 2013 Sep;
127(6):762-71.
PMID: 23992036
Long-term nicotine exposure induces alterations in dopamine transmission in nucleus accumbens that sustain the reinforcing effects of smoking. One approach to understand the adaptive changes that arise involves measurement of...